Homepage
Author:
AB Science
Posted Date:
February 24, 2026
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
AB Science
February 24, 2026
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
AB Science
February 9, 2026
AB Science reçoit un avis d’autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant
AB Science
January 29, 2026
